Tirzepatide (Spartina) in Obese Kidney Transplant Recipients

NCT07423247 on ClinicalTrials.gov · last registry update 2026-02-20

A small phase 4 — 30 participants, against a typical 75. Its estimated completion date, July 2026, has passed with no update to the record. Primary outcome, as filed: Percent Change in Body Weight From Baseline at Week 24. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here.

Status: RECRUITING
Phase: P4
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Shahid Beheshti University of Medical Sciences
Sponsor type: Other
Enrollment: 30
Started: 2026-01-01
Primary completion: 2026-07 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change in Body Weight From Baseline at Week 24

Conditions studied

Tirzepatide

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.